Literature DB >> 2206791

In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

N A Helsby1, S A Ward, R E Howells, A M Breckenridge.   

Abstract

The metabolic activation of the arylbiguanide antimalarials proguanil (PG) and chlorproguanil (CPG) has been investigated in liver microsomes from three human livers. All three microsomal preparations activated the biguanides. The kinetic parameters for PG metabolism to cycloguanil (CG) were Km 21.8, 29.6 and 26.4 microM and Vmax 1.5, 5.9, and 8.2 pmol min-1 mg-1. The values for CPG conversion to chlorcycloguanil (CCG) were Km 12.9, 19.7 and 26.1 microM and Vmax 5.7, 4.8 and 3.6 pmol min-1 mg-1. The metabolic activation of both biguanides was competitively inhibited by the anticonvulsant mephenytoin. Sparteine and tolbutamide had no effect on biguanide metabolism. These data suggest an involvement of the mephenytoin hydroxylase enzyme, which exhibits a genetic polymorphism in man, in the metabolic activation of the biguanide antimalarials.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2206791      PMCID: PMC1368230          DOI: 10.1111/j.1365-2125.1990.tb03777.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  The determination of enzyme inhibitor constants.

Authors:  M DIXON
Journal:  Biochem J       Date:  1953-08       Impact factor: 3.857

2.  Interactions between nutritional factors and drug biotransformations in man.

Authors:  A P Alvares; K E Anderson; A H Conney; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

Review 3.  Genetic and environmental factors affecting drug disposition in man.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

4.  Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation.

Authors:  N S Oates; R R Shah; J R Idle; R L Smith
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

5.  Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.

Authors:  A R Boobis; S Murray; G C Kahn; G M Robertz; D S Davies
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

6.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

7.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 8.  Contribution of environmental factors to variability in human drug metabolism.

Authors:  C T Dollery; H S Fraser; J C Mucklow; C J Bulpitt
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

10.  Pharmacogenetics of tolbutamide metabolism in humans.

Authors:  J Scott; P L Poffenbarger
Journal:  Diabetes       Date:  1979-01       Impact factor: 9.461

View more
  17 in total

Review 1.  Inborn 'errors' of drug metabolism. Pharmacokinetic and clinical implications.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 2.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.

Authors:  J Wangboonskul; N J White; F Nosten; F ter Kuile; R R Moody; R B Taylor
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.

Authors:  M D Edstein; G D Shanks; P Teja-Isavadharm; K H Rieckmann; H K Webster
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

5.  The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.

Authors:  J D Wright; N A Helsby; S A Ward
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation.

Authors:  K Chiba; A Saitoh; E Koyama; M Tani; M Hayashi; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

8.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

9.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.

Authors:  D J Birkett; D Rees; T Andersson; F J Gonzalez; J O Miners; M E Veronese
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

10.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.